A prescription event monitoring study to assess safety and health outcomes of Airtec SF® (salmeterol fluticasone propionate combination) in Indian population


  • Ashok A. Mahashur Consultant Pulmonologist, Hinduja Hospital, Mumbai, Maharashtra, India
  • K. Korukonda Medical Services, Glenmark Pharmaceuticals, Mumbai, Maharashtra, India
  • Vikram Sobti Medical Services, Glenmark Pharmaceuticals, Mumbai, Maharashtra, India
  • Amit Bhargava Medical Services, Glenmark Pharmaceuticals, Mumbai, Maharashtra, India


Asthma, Obstructive lung disease, Salmeterol, Fluticasone propionate, Prescription event monitoring


Background: Asthma management has been fraught with several challenges especially for partly or uncontrolled cases. Incremental dosage strategy with salmeterol, fluticasone propionate combination offers stable yet effective control of symptoms preventing further exacerbations. However, there is limited evidence available on the need and safety profile of this incremental dosage strategy with the combination especially in Indian settings. To examine the safety and adverse clinical outcomes of Airtec SF when prescribed in patients with well- or poorly controlled persistent asthma.

Methods: Based on the principle of prescription event monitoring (PEM) for safety reporting, this study was conducted at 20 centers across India. PEM study booklets with study questionnaire were provided to capture information related to adverse “events” during the observation period of 30 days.

Results: Data of 384 patients were analyzed, with a mean age 44.5 years. 39% (n=150) were newly diagnosed and 61% (n=234) being in poorly controlled asthma status (i.e., partly or uncontrolled asthma). Of them, 42% (161), 44% (n=169) and 14% (54) patients were diagnosed with mild, moderate or severe persistent asthma, respectively. These were prescribed with metered-dose inhaler (n=187) or dry powder inhaler (n=197) formulations. 56% (n=216) patients suffered from concomitant allergic rhinitis. Among newly diagnosed patients with moderate to severe asthma dosage were tapered in 5.5% (n=3) cases. Dosage consistency was well-maintained in 98.2% (n=155) among partial or uncontrolled asthmatics with moderate to severe asthma with exacerbation rate of 1.9% (n=3). Adverse events including infective pneumonitis and upper respiratory tract infection were transient with none requiring treatment withdrawal.

Conclusion: Use of Airtec SF was safe and well-tolerated with a negligible rate of exacerbations in Indian population especially amongst poorly controlled asthma patients.


O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392-7.

National Institutes of Health, National Heart, Lung, and Blood Institute. Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Institutes of Health; 2012.

Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O’Byrne PM, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med. 1999;160(2):594-9.

Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836-44.

Perrio MJ, Wilton LV, Shakir SA. A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance. Drug Saf. 2007;30(8):681-95.

Mann RD. Prescription-event monitoring -recent progress and future horizons. Br J Clin Pharmacol. 1998;46:195-201.

FitzGerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther. 2005;27(4):393-406.

Dahl R, Chuchalin A, Gor D, Yoxall S, Sharma R. EXCEL: a randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med. 2006;100(7):1152-62.

Ferguson GT, Calvezley PM, Andeison ZA, Celli B, Jenkims C, Jones PN, et al. The towards a revolution in COPD health (TORCH) study: fluticasone preprionate/salmeterol in well tolerated in patients with COPD over 3 years. Chest. 2006;130:178S.




How to Cite

Mahashur, A. A., Korukonda, K., Sobti, V., & Bhargava, A. (2017). A prescription event monitoring study to assess safety and health outcomes of Airtec SF® (salmeterol fluticasone propionate combination) in Indian population. International Journal of Basic & Clinical Pharmacology, 3(6), 1086–1089. Retrieved from https://www.ijbcp.com/index.php/ijbcp/article/view/1192



Original Research Articles